EX-10.1
Summit Therapeutics Inc.
**SECURITIES PURCHASE AGREEMENT **
This **SECURITIES PURCHASE AGREEMENT **(this “Agreement”) is dated as of September 28, 2026, by and between Summit Therapeutics Inc., a Delaware corporation (the “Company”), and AstraZeneca Holdings B.V., a Dutch private limited liability company (the “Investor”).
**WHEREAS, **the Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) and/or Rule 506 of Regulation D promulgated thereunder of the U.S. Securities Act of 1933 (the “Securities Act”);
**WHEREAS, **the Company desires to sell to the Investor, and the Investor desires to purchase from the Company, upon the terms and subject to the conditions stated in this Agreement, shares (the “Shares”) of the Convertible Preferred Stock; and
…